trending Market Intelligence /marketintelligence/en/news-insights/trending/2wXLMwb3e-7TddF1jQVO8Q2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Assertio to sell rights to pain drug Gralise to Alvogen in $127.5M deal

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Assertio to sell rights to pain drug Gralise to Alvogen in $127.5M deal

Assertio Therapeutics Inc. is selling all rights related to its pain drug Gralise to Pine Brook, N.J.-based privately held company Alvogen Inc. for a transaction value of about $127.5 million.

Under the agreement, Lake Forest, Ill.-based Assertio will receive $75 million in cash upon closing and the balance in the form of a royalty on the first $70 million in net sales of Gralise, which is used to treat pain from damaged nerves that occurs during healing of the viral infection shingles.

The companies expect the majority of the royalties to be paid in the first calendar year.

Assertio's President and CEO, Arthur Higgins, said the sale will allow the company to focus on anti-inflammatory drug Cambia and another pain drug Zipsor.

The divestment will also give the company flexibility for future business development opportunities, Higgins noted in a Dec. 12 press release.

The transaction is expected to close in early January 2020, subject to regulatory approval.

The company added that it would specify the financial impact of the sale following the closing of the transaction.